Nick Upright is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations group.
Prior to joining the firm, Nick completed his doctoral training at Icahn School of Medicine at Mount Sinai where he gained extensive experience in behavioral and biological sciences. As a graduate student in the neuroscience department, he used chemogenetic and pharmacological technologies in a nonhuman primate model to study the role of neuromodulatory circuits in cognition and working memory. In addition, he examined how modulation of cholinergic signaling impacts age-related cognitive deficits and connectivity dynamics.
Nick Upright is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations group.
Prior to joining the firm, Nick completed his doctoral training at Icahn School of Medicine at Mount Sinai where he gained extensive experience in behavioral and biological sciences. As a graduate student in the neuroscience department, he used chemogenetic and pharmacological technologies in a nonhuman primate model to study the role of neuromodulatory circuits in cognition and working memory. In addition, he examined how modulation of cholinergic signaling impacts age-related cognitive deficits and connectivity dynamics.
- Ph.D., Neuroscience, Icahn School of Medicine at Mount Sinai, 2022
- B.S., Neuroscience, Davidson College, 2014
- U.S. Patent and Trademark Office
- Ph.D., Neuroscience, Icahn School of Medicine at Mount Sinai, 2022
- B.S., Neuroscience, Davidson College, 2014
- U.S. Patent and Trademark Office
Select Publications
- Co-author with M.G. Baxter, “Effects of nicotinic antagonists on working memory performance in young rhesus monkeys,” Neurobiology of Learning and Memory, 2021
- Co-author with M.G. Baxter, “Prefrontal cortex and cognitive aging in macaque monkeys,” 83(11) American Journal of Primatology, 2021
- Co-author with M.G. Baxter, “Effect of chemogenetic actuator drugs on prefrontal corte4x-dependent working memory in nonhuman primates,” 45(11) Neuropsychopharmacology, 2020
- Co-author with S.W. Brookshire, W. Schnebelen, C.G. Damatac, P.R. Hof, P.G.F. Browning, P.L. Croxson, P.H. Rudebeck, and M.G. Baxter, “Behavioral effect of chemogenetic inhibition is directly related to receptor transduction in rhesus monkeys,” 38(37) Journal of Neuroscience, 2018
Select Publications
- Co-author with M.G. Baxter, “Effects of nicotinic antagonists on working memory performance in young rhesus monkeys,” Neurobiology of Learning and Memory, 2021
- Co-author with M.G. Baxter, “Prefrontal cortex and cognitive aging in macaque monkeys,” 83(11) American Journal of Primatology, 2021
- Co-author with M.G. Baxter, “Effect of chemogenetic actuator drugs on prefrontal corte4x-dependent working memory in nonhuman primates,” 45(11) Neuropsychopharmacology, 2020
- Co-author with S.W. Brookshire, W. Schnebelen, C.G. Damatac, P.R. Hof, P.G.F. Browning, P.L. Croxson, P.H. Rudebeck, and M.G. Baxter, “Behavioral effect of chemogenetic inhibition is directly related to receptor transduction in rhesus monkeys,” 38(37) Journal of Neuroscience, 2018
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Cancer biology
- CAR-T cells
- Cell biology
- Cellular biology
- Cellular immunology
- Immunobiology
- Immunology
- Neurobiology
- T cell biology
Therapeutics and Drug Discovery
- Neuropharmacology
- Pharmacodynamics
- Pharmacology
- Small molecules
- Vaccines
Diagnostics and Medical Devices
- Biomedical devices
- Medical devices
- Neuroimaging
Miscellaneous
- Cancer
- Psychology
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Cancer biology
- CAR-T cells
- Cell biology
- Cellular biology
- Cellular immunology
- Immunobiology
- Immunology
- Neurobiology
- T cell biology
Therapeutics and Drug Discovery
- Neuropharmacology
- Pharmacodynamics
- Pharmacology
- Small molecules
- Vaccines
Diagnostics and Medical Devices
- Biomedical devices
- Medical devices
- Neuroimaging
Miscellaneous
- Cancer
- Psychology
Eight Sleep will use the funding to supercharge its AI roadmap, starting with the development of the world’s first Sleep Agent. This marks a breakthrough in applying large language models to human physiology, going beyond conversation to deliver real-time, real-world optimization. The funding will also support Eight Sleep’s entry into the medical space, as the company is developing AI-powered solutions for medical sleep challenges, starting with menopausal sleep and sleep apnea. Eight Sleep is also targeting FDA approval for certain applications.
The Wilson Sonsini team advising Eight Sleep on IP matters related to the transaction includes Bill Barrett, Darby Chan, Seth Lee, and Nick Upright.
For more information, please see Eight Sleep’s news release.
- Privacy Policy
- Terms of Use
- Accessibility